Biomea Fusion Inc
Research Biomea Fusion Inc (BMEA) on Bullrun: market cap USD 125.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBMEA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 125.40M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.33M
- Free cash flow-USD 10.03M
Valuation Snapshot
latest market cap is USD 125.40M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 61.80M | -USD 70.37M | n/a | -1.18 | USD 55.81M | USD 1.59M | USD 29.55M |
| FY2024 | USD 0 | -USD 138.43M | -USD 120.26M | n/a | -3.83 | USD 58.28M | USD 8.77M | USD 51.57M |
| FY2023 | USD 0 | -USD 117.26M | -USD 99.96M | n/a | -3.44 | USD 176.87M | USD 10.30M | USD 169.24M |
| FY2022 | USD 1.24B | -USD 81.83M | -USD 63.45M | n/a | -2.8 | USD 111.90M | USD 2.58M | USD 108.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 125.40M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 89.65M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 140.89M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 518.45M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 247.81M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 216.91M | n/a | n/a | n/a |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biomea Fusion Inc's market cap?
Biomea Fusion Inc's market capitalization is USD 125.40M.
What does Biomea Fusion Inc do?
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.